Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Biomacromolecules ; 19(1): 112-131, 2018 01 08.
Article in English | MEDLINE | ID: mdl-29211954

ABSTRACT

Chitosan (CS) shows in vitro and in vivo efficacy for siRNA delivery but with contradictory findings for incompletely characterized systems. For understanding which parameters produce effective delivery, a library of precisely characterized chitosans was produced at different degrees of deacetylation (DDAs) and average molecular weights (Mn). Encapsulation and transfection efficiencies were characterized in vitro. Formulations were selected to examine the influence of Mn and N:P ratio on nanoparticle uptake, metabolic activity, genotoxicity, and in vitro transfection. Hemocompatibility and in vivo biodistribution were then investigated for different Mn, N:P ratios, and doses. Nanoparticle uptake and gene silencing correlated with increased surface charge, which was obtained at high DDA and high Mn. A minimum polymer length of ∼60-70 monomers (∼10 kDa) was required for stability and knockdown. In vitro knockdown was equivalent to lipid control with no metabolic or genotoxicity. An inhibitory effect of serum on biological performance was dependent on DDA, Mn, and N:P. In vivo biodistribution in mice show accumulation of nanoparticles in kidney with 40-50% functional knockdown.


Subject(s)
Amines/metabolism , Biocompatible Materials/chemistry , Chitosan/administration & dosage , Gene Silencing , Nanoparticles/chemistry , Phosphates/metabolism , RNA, Small Interfering/administration & dosage , Acetylation , Blood , Cell Line, Tumor , Chitosan/chemistry , Chitosan/pharmacokinetics , Comet Assay , Epithelial Cells/metabolism , Gene Expression/drug effects , Humans , Hydrogen-Ion Concentration , Kidney Tubules, Proximal/cytology , Kidney Tubules, Proximal/metabolism , Molecular Weight , Nanoparticles/toxicity , Real-Time Polymerase Chain Reaction , Tissue Distribution
2.
Mol Cell Biol ; 32(19): 3823-37, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22826433

ABSTRACT

The selective estrogen receptor downregulator (SERD) fulvestrant can be used as second-line treatment for patients relapsing after treatment with tamoxifen, a selective estrogen receptor modulator (SERM). Unlike tamoxifen, SERDs are devoid of partial agonist activity. While the full antiestrogenicity of SERDs may result in part from their capacity to downregulate levels of estrogen receptor alpha (ERα) through proteasome-mediated degradation, SERDs are also fully antiestrogenic in the absence of increased receptor turnover in HepG2 cells. Here we report that SERDs induce the rapid and strong SUMOylation of ERα in ERα-positive and -negative cell lines, including HepG2 cells. Four sites of SUMOylation were identified by mass spectrometry analysis. In derivatives of the SERD ICI164,384, SUMOylation was dependent on the length of the side chain and correlated with full antiestrogenicity. Preventing SUMOylation by the overexpression of a SUMO-specific protease (SENP) deSUMOylase partially derepressed transcription in the presence of full antiestrogens in HepG2 cells without a corresponding increase in activity in the presence of agonists or of the SERM tamoxifen. Mutations increasing transcriptional activity in the presence of full antiestrogens reduced SUMOylation levels and suppressed stimulation by SENP1. Our results indicate that ERα SUMOylation contributes to full antiestrogenicity in the absence of accelerated receptor turnover.


Subject(s)
Estradiol/analogs & derivatives , Estrogen Antagonists/pharmacology , Estrogen Receptor alpha/metabolism , Sumoylation/drug effects , Cell Line, Tumor , Estradiol/chemistry , Estradiol/pharmacology , Estrogen Antagonists/chemistry , Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/genetics , Fulvestrant , HEK293 Cells , Hep G2 Cells , Humans , Molecular Docking Simulation , Point Mutation , Protein Structure, Tertiary
3.
Nucleic Acids Res ; 35(10): 3465-77, 2007.
Article in English | MEDLINE | ID: mdl-17478511

ABSTRACT

Although artificial C2-H2 zinc fingers can be designed to recognize specific DNA sequences, it remains unclear to which extent nuclear receptor C4 zinc fingers can be tailored to bind novel DNA elements. Steroid receptors bind as dimers to palindromic response elements differing in the two central base pairs of repeated motifs. Predictions based on one amino acid-one base-pair relationships may not apply to estrogen receptors (ERs), which recognize the two central base pairs of estrogen response elements (EREs) via two charged amino acids, each contacting two bases on opposite DNA strands. Mutagenesis of these residues, E203 and K210 in ERalpha, indicated that both contribute to ERE binding. Removal of the electric charge and steric constraints associated with K210 was required for full loss of parental DNA-binding specificity and recognition of novel sequences by E203 mutants. Although some of the new binding profiles did not match predictions, the double mutation E203R-K210A generated as predicted a mutant ER that was transcriptionally active on palindromes of PuGCTCA motifs, but not on consensus EREs. This study demonstrates the feasibility of designing C4 zinc finger mutants with novel DNA-binding specificity, but also uncovers limitations of this approach.


Subject(s)
Estrogen Receptor alpha/chemistry , Estrogen Receptor alpha/genetics , Response Elements , Zinc Fingers , Amino Acids/chemistry , Base Sequence , Binding Sites , Consensus Sequence , DNA/chemistry , DNA/metabolism , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Estrogen Receptor alpha/metabolism , Estrogen Receptor beta/chemistry , Estrogen Receptor beta/metabolism , HeLa Cells , Humans , Models, Molecular , Mutagenesis , Protein Binding , Protein Engineering , Protein Structure, Tertiary , Transcriptional Activation
SELECTION OF CITATIONS
SEARCH DETAIL
...